Day 2 - Tuesday, May 19 2026Tuesday, 19 May 2026 - ET (Eastern Time, GMT-05:00)

This session explores how automation transforms Medicaid operations, eliminating repetitive, manual tasks and replacing them with timely, actionable financial insight. Across the full financial lifecycle, invoice processing flows directly into Gross‑To‑Net, leveraging dynamic dashboards combined with AI‑driven anomaly detection to deliver real‑time visibility into operational throughput and financial performance, surfacing discrepancies before they escalate into material risk.

• Analysis of state enforcement actions and penalty structures following initial compliance cycles
• Operational translation of complex state requirements into decision-tree frameworks for pricing teams
• Trade secret protection challenges in examination of regulatory requests for supporting data and manufacturer response strategies
• State vs. Federal precedence: Legal landscape analysis where states are establishing independent transparency requirements beyond federal mandates

What factors do PDABs consider when evaluating drug value beyond cost? Explore how states assess clinical impact, patient outcomes, and market dynamics

• Walk through the complete process when a drug comes under PDAB review - from notification through assessment to decision-making
• Best practices for transparency and collaboration between manufacturers, PDABs and state agencies

• Understand the intricacies of state-level pricing transparency laws and how they impact your pricing strategy

• Walk through real-world scenarios and challenges faced when increasing product prices, from the regulatory to the practical

• Intersection of state price reporting and Most Favored Nation frameworks

• Learn best practices for managing relationships with partners who store, ship, and process financial transactions for your products
• Understand how to monitor and validate 3PL chargeback processing to prevent revenue leakage and operational errors
• Develop strategies for delivering constructive feedback and maximizing value from your 3PL investment through structured communication and performance metrics

Forecasting and GTN consolidation have always presented challenges in aligning human and data resources to present a reasonable and actionable plan for growth and financial reporting. Seemingly constant changes to new areas of uncertainty – 340B, MFN, Tariffs – are adding dimensions to this complexity. Focusing on the basics and identifying more efficient processes to manage internal capital can help to mitigate these challenges.

• Benchmark your pricing performance against industry standards
• Review 2025-2026 data on average pre/post deal variance across multiple channels, scenario modeling frequency, and common operational challenges to identify where your organization stands
• Understand how leading organizations are using quantitative analysis to navigate IRA negotiations, coverage gap redesign impacts, and cross-functional pricing decisions in the current regulatory environment
• Optimize operational frameworks through industry best practices
• Discover proven approaches for managing pricing complexity, improving cross-functional collaboration, and implementing sustainable processes that drive both compliance and commercial success

• Master evolving competitive dynamics between originators, biosimilars, and generics - examining real-world pricing strategies, PBM pressures, and channel optimization approaches across product types
• Balance profitability amid complex government program requirements, wholesaler fee structures, and membership validation challenges unique to biosimilar and generic business models
• Optimize operational execution across distribution channels while managing intricate chargeback processes and contract pharmacy relationships in an increasingly competitive landscape
• Analyze how IRA implementation, Medicare Part D redesign, and emerging PBM policies are reshaping market access opportunities and contracting approaches for non-brand manufacturers
• Future-proof your strategy by understanding shifting payor dynamics, regulatory requirements, and market entrant impacts on biosimilar and generic positioning

• Price erosion management strategies
• Contract renegotiation tactics as market matures
• Portfolio optimization decisions (when to exit vs. invest)
• Payer relationship evolution from launch to maturity

• Implement systematic approaches for tracking ownership changes, validating eligibility across complex networks, and maintaining contract compliance during M&A transitions and portfolio restructuring
• Create scalable processes for managing multiple GPO memberships, PBM relationships, and contract hierarchies while ensuring data accuracy and preventing revenue leakage across diverse technology platforms
• Establish comprehensive audit trail and exception handling procedures
• Build defensible documentation systems that support complex ownership validations, handle non-standard scenarios, and maintain compliance readiness for increasingly sophisticated payer and regulatory audits